biomarkers for clinical drug devel-
opment. Bioanalysis, 2, 237–247.
Selby, C. (1999). Interference in immunoassay. Annals of Clinical Biochemistry, 36,
704–721.
Staples, E., Ingram, R. J., Atherton, J. C.
/d y
701 Syntaxin 6 S9067 M y y y
702 Syntaxin 8 S8945 P n/d n/d y
703 α-Synuclein S3062 P y n/d y
704 Negative Control NA
705 Tal T1075 P y y y
706 Tal T1200 P y y y
707 TAP T1076 M
rence methods demon-
strated.
Details regarding the necessity of AQA can be
found in Memorandum A 704 of the German As-
sociation for the Water Sector, Wastewater, and
Waste Materials (Deutsche Vereinigung
061238.1 P n/d n/d y
703 α-Synuclein S3062 29219, 6622 SNCA,Snca NP_062042.1,NP_009292.1 P y n/d y
704 Negative Control
705 Tal T1075 90678, 227738 Lrsam1,LRSAM1 NP_612370.3,NP_955006.1 P y y y
706 Tal
061238.1 P n/d n/d y
703 α-Synuclein S3062 29219, 6622 SNCA,Snca NP_062042.1,NP_009292.1 P y n/d y
704 Negative Control NA
705 Tal T1075 90678, 227738 Lrsam1,LRSAM1 NP_612370.3,NP_955006.1 P y y y
706 Tal